Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers

An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers

The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.

Inclusion Criteria:

• Body Mass index (BMI) 18-30 kg/m2, inclusive.
• Clinically normal findings in physical examination, ECG, vital signs, clinical chemistry, haematology & urinalysis, as judged by the investigator

Exclusion Criteria:

• Healthy volunteers who have been exposed to radiation levels above background (eg through X-ray examination) of >5 mSv in the last year, >10 mSv over the last 5 years or a cumulative total of >1 mSv per year of life
• Clinically significant illness within the 2 weeks prior to dosing, as judged by the investigator
• Use of prescribed medication (including St. John's Wort) during the 3 weeks prior to dosing or use of over the counter drugs (including herbals, vitamins and minerals) during 1 week prior to dosing (other than occasional paracetamol use)